文献速递炎症性肠病

较高的阿达木单抗浓度与肛周瘘管型克罗恩病患者完全瘘管愈合相关

Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-04-29

肛周瘘管可发生于约30%的克罗恩病(CD)患者,与生活质量受损及住院和手术率增加相关。抗肿瘤坏死因子治疗是肛周瘘管型CD的药物治疗基石,主要为英夫利西单抗和阿达木单抗(ADM)。本研究探讨维持期ADM浓度与完全瘘管愈合(CFH)的关联,并确定CFH的最佳ADM浓度阈值。

要点

  • 肛周瘘管可发生于约30%的克罗恩病患者
  • 抗肿瘤坏死因子治疗是肛周瘘管型克罗恩病的药物治疗基石
  • 本研究探讨维持期阿达木单抗浓度与完全瘘管愈合的关联

核心结论

  • 本研究探讨维持期阿达木单抗浓度与完全瘘管愈合的关联,并确定完全瘘管愈合的最佳阿达木单抗浓度阈值。

研究设计与样本

  • 研究设计为探讨维持期阿达木单抗浓度与完全瘘管愈合关联并确定最佳浓度阈值的研究,原文未报告具体样本量。

主要发现

  • 原文未报告具体研究结果数值。

关键数值与推荐

  • 原文未报告完全瘘管愈合的阿达木单抗浓度阈值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出关于阿达木单抗浓度与肛周瘘管型克罗恩病结局关联的数据有限,且多来自小型回顾性研究。
  • 原文指出肛周瘘管型克罗恩病完全瘘管愈合的最佳阿达木单抗浓度仍有待阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Perianal fistulas can develop in around 30% of patients with Crohn's disease (CD) and are associated with impaired quality of life and worse outcomes including increased rates of hospitalizations and surgeries.1 The cornerstone of pharmacologic treatment for perianal fistulizing CD is anti-tumor necrosis factor therapy, mainly infliximab and adalimumab (ADM).2 Therapeutic drug monitoring (TDM) can be used to identify potential pharmacokinetic and pharmacodynamic issues and avoid or manage unwanted outcomes, such as primary nonresponse and secondary loss of response.3 There are several exposure-response relationship data demonstrating a positive correlation between serum infliximab concentrations and favorable objective therapeutic outcomes in patients with perianal fistulizing CD.4 Nevertheless, there are only limited data, which is mostly from small retrospective studies regarding the association of ADM concentration and outcomes in patients with perianal fistulizing CD.4-8 Furthermore, the optimal ADM concentration for fistula healing still remains to be elucidated. This is clinically important because drug concentration cutoffs are used in reactive and proactive TDM algorithms to define therapeutic drug concentrations. This study investigates the association of maintenance ADM concentrations with complete fistula healing (CFH) and identifies an optimal ADM concentration threshold for CFH.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Papamichael K, Centritto A, Guillo L, et al. Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn's Disease. Clin Gastroenterol Hepatol. 2024. PMID: 38692557. doi:10.1016/j.cgh.2024.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。